PRELUDE THERAPEUTICS INC
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | — | $212.2M | $218.3M |
| FY2021 | — | $285.9M | $31.8M |
| FY2022 | — | $195.4M | $30.6M |
| FY2023 | — | $237.1M | $25.3M |
| FY2024 | — | $131.5M | $12.5M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | — | $212.2M | $218.3M |
| FY2021 | — | $285.9M | $31.8M |
| FY2022 | — | $195.4M | $30.6M |
| FY2023 | — | $237.1M | $25.3M |
| FY2024 | — | $131.5M | $12.5M |